2082. Effectiveness of Bivalent mRNA Vaccines in Preventing SARS-CoV-2 Infection Among Children Aged 5-17 years: an Evaluation of Multicenter Prospective Cohorts, United States, September 2022 - January 2023

BACKGROUND: The bivalent mRNA COVID-19 vaccine booster dose, composed of mRNA from ancestral and Omicron BA.4/BA.5 strains, was recommended for adolescents aged ≥12 years on September 1, 2022, and for children aged 5–11 years on October 12, 2022. However, data demonstrating the effectiveness of biva...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldstein, Leora R, Britton, Amadea, Beacham, Lauren, Wiegand, Ryan E, Ruffin, Jasmine, Briggs-Hagen, Melissa, Fowlkes, Ashley, Burgess, Jefferey L, Caban-Martinez, Alberto, Chu, Helen Y, Englund, Janet A, Hegmann, Kurt, Jeddy, Zuha, Lutrick, Karen, Martin, Emily T, Meece, Jennifer K, Midgley, Claire, Monto, Arnold, Newes-Adeyi, Gabriella, Odame-Bamfo, Leah, Olsho, Lauren E W, Saydah, Sharon, Smith, Ning, Steinhardt, Laura, Tyner, Harmony, Yoon, Sarang K, Gaglani, Manjusha, Naleway, Allison L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678731/
http://dx.doi.org/10.1093/ofid/ofad500.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678731/
http://dx.doi.org/10.1093/ofid/ofad500.152

Ejemplares similares